<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2025.6.OZOZ.2</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-1373</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ, ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ, СОЦИОЛОГИЯ И ИСТОРИЯ МЕДИЦИНЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PUBLIC HEALTH AND HEALTHCARE ORGANIZATION, SOCIOLOGY AND HISTORY OF MEDICINE</subject></subj-group></article-categories><title-group><article-title>Эпидемиологические особенности акральной меланомы кожи в крупном промышленном регионе (Самарская область)</article-title><trans-title-group xml:lang="en"><trans-title>Epidemiological features of acral melanoma in a large industrial region (Samara region)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2316-7482</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Неретин</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Neretin</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Неретин Евгений Юрьевич. Д-р мед. наук, врач-онколог высшей категории консультативного отделения № 1; профессор кафедры хирургических болезней с курсом онкологии</p><p>ул. Солнечная, д. 50, г. Самара, 443029</p><p>ул. Чапаевская, д. 227, г. Самара, 443001</p></bio><bio xml:lang="en"><p>Evgeniy Yu. Neretin. Dr. Sci. (Med.), oncologist of the highest category, Advisory Department No. 1; Professor, Department of Surgical Diseases with a Course in Oncology</p><p>Solnechnaya St., 50, Samara, 443029</p><p>Chapaevskaya St., 227, Samara, 443001</p></bio><email xlink:type="simple">evg.neretin2002@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4460-9136</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титов</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Titov</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Титов Константин Сергеевич. Д-р мед. наук, профессор, ведущий научный сотрудник; профессор кафедры онкологии и рентгенорадиологии имени академика В.П. Харченко</p><p>2-й Боткинский проезд, д. 5, г. Москва, 125284</p><p>ул. Миклухо-Маклая, д. 6, г. Москва, 117198</p></bio><bio xml:lang="en"><p>Konstantin S. Titov. Dr. Sci. (Med.), Professor, Leading Researcher; Professor, Department of Oncology and Roentgenology named after Academician V.P. Kharchenko</p><p>2-y Botkinskiy proezd, 5, Moscow, 125284</p><p>Miklukho-Maklaya st., 6, Moscow, 117198</p></bio><email xlink:type="simple">ks-titov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2715-3933</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якушева</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakusheva</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Якушева Татьяна Александровна. Заведующая онкологическим отделением № 1 ЦАОП</p><p>2-й Боткинский проезд, д. 5, г. Москва, 125284</p></bio><bio xml:lang="en"><p>Tat'yana A. Yakusheva. Head of the Oncology Department No. 1, Central Asian Oncology Center</p><p>2-y Botkinskiy proezd, 5, Moscow, 125284</p></bio><email xlink:type="simple">t.a.y.2017@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Самарский областной клинический онкологический диспансер; Медицинский университет «Реавиз»<country>Россия</country></aff><aff xml:lang="en">Samara Regional Clinical Oncology Dispensary; Medical University "Reaviz"<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Московский многопрофильный научно-клинический центр им. С.П. Боткина; Российский университет дружбы народов имени Патриса Лумумбы<country>Россия</country></aff><aff xml:lang="en">Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Patrice Lumumba Peoples' Friendship University of Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Московский многопрофильный научно-клинический центр им. С.П. Боткина<country>Россия</country></aff><aff xml:lang="en">Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>03</month><year>2026</year></pub-date><volume>15</volume><issue>6</issue><fpage>146</fpage><lpage>155</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Неретин Е.Ю., Титов К.С., Якушева Т.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Неретин Е.Ю., Титов К.С., Якушева Т.А.</copyright-holder><copyright-holder xml:lang="en">Neretin E.Y., Titov K.S., Yakusheva T.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/1373">https://vestnik.reaviz.ru/jour/article/view/1373</self-uri><abstract><p>Актуальность исследования заключается в том, что акральная меланома кожи представляет собой редкий подтип меланомы, который составляет около 3% среди всех случаев меланомы кожи с уникальными гистологическими, биологическими и эпидемиологическими особенностями. По мнению ряда авторов, она чаще встречается у лиц азиатского и африканского происхождения, характеризуется поздней диагностикой и высокой злокачественностью, что делает её изучение актуальным для улучшения скрининга и лечения, особенно в регионах с промышленной нагрузкой.</p><p>Целью исследования было изучение особенностей акральной меланомы кожи на примере крупного промышленного региона (Самарская область) для выявления динамики заболеваемости, смертности и сравнения с меланомой кожи других локализаций.</p><p>Материалом и методами послужили данные ретроспективного анализа о 218 пациентах с акральной меланомой кожи (локализация: ладони, подошвы, пальцы, ногтевое ложе, тыльные поверхности кистей и стоп), прошедших обследование и лечение в Самарской области за период с 2000–2022 годы. Из статистических методов был проведён расчёт абсолютных и относительных показателей, грубых показателей заболеваемости и смертности на 100 тысяч населения, анализ трендов (линейная и полиномиальная аппроксимация), сравнение с общими данными по меланоме кожи.</p><sec><title>Результаты</title><p>Результаты. Были получены результаты, свидетельствующие, что абсолютное количество случаев акральной меланомы выросло с 65 (2000–2010 годы) до 153 (2011–2021 годы), темп прироста составил 135,38% (против 39,41% для меланомы кожи). Грубый показатель заболеваемости: 0,06–0,3 на 100 тысяч населения (против 5,17–8,36 для меланомы кожи). Удельный вес акральной меланомы — 3,01–4,98%. Смертность растёт (линейный тренд  y=0,025x + 0,0204; R²=0,5501). Соотношение заболевших мужчин и женщин — 1:2,53, умерших — 1:1,81, указывая на более агрессивное течение у женщин, заболевших акральной меланомы кожи.</p></sec><sec><title>Выводы</title><p>Выводы. Акральная меланома кожи — самостоятельный подтип с высоким темпом роста заболеваемости и смертности, требующий специализированных скрининговых программ. Результаты экстраполируемы на Российскую Федерацию, подчёркивая необходимость дальнейших исследований. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Acral melanoma of the skin is a rare subtype of melanoma, accounting for approximately 3% of all melanoma cases, with unique histological, biological, and epidemiological characteristics. It is more common in individuals of Asian and African descent, characterized by late diagnosis and high malignancy, making its study crucial for improving screening and treatment, particularly in industrially developed regions.</p></sec><sec><title>Objective</title><p>Objective. To investigate the characteristics of acral melanoma of the skin in a large industrial region (Samara Region) by analyzing the dynamics of incidence, mortality, and comparison with melanomas of other localizations.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. A retrospective analysis was conducted on data from 218 patients with acral melanoma (localization: palms, soles, fingers, nail bed, dorsal surfaces of hands and feet) diagnosed and treated in the Samara Region from 2000 to 2022. Statistical methods included calculation of absolute and relative indicators, crude incidence and mortality rates per 100,000 population, trend analysis (linear and polynomial approximation), and comparison with general skin melanoma data.</p></sec><sec><title>Results</title><p> Results. The absolute number of acral melanoma cases increased from 65 (2000–2010) to 153 (2011–2021), with a growth rate of 135.38% (compared to 39.41% for other melanomas). Crude incidence rates ranged from 0.06 to 0.3 per 100,000 populations (compared to 5.17–8.36 for other melanomas). Acral melanoma accounted for 3.01–4.98% of all melanoma cases. Mortality increased (linear trend y=0.025x + 0.0204; R²=0.5501). The male-to-female ratio of cases was 1:2.53, and for deaths, 1:1.81, indicating a more aggressive course in women.</p></sec><sec><title>Conclusions</title><p>Conclusions. Acral melanoma is a distinct subtype with a high growth rate in incidence and mortality, necessitating specialized screening programs. The findings are extrapolatable to the Russian Federation, highlighting the need for further research.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>акральная меланома кожи [D008545 (Melanoma)]</kwd><kwd>эпидемиология [D004813]</kwd><kwd>заболеваемость [D015994]</kwd><kwd>смертность [D009026]</kwd><kwd>меланома кожи [D008545 (Melanoma)]</kwd><kwd>Самарская область [–]</kwd><kwd>анализ тренда [D000704 (Analysis of Variance)*]</kwd><kwd>ладони [D010163]</kwd><kwd>подошвы [D005528 (Foot)]</kwd><kwd>ногтевое ложе [D009262 (Nails)]</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acral melanoma [D008545 (Melanoma)]</kwd><kwd>epidemiology &#13;
[D004813]</kwd><kwd>incidence [D015994]</kwd><kwd>mortality [D009026]</kwd><kwd>skin melanoma [D008545 (Melanoma)]</kwd><kwd>Samara Region [–]</kwd><kwd>trend analysis [D000704 (Analysis of Variance)*]</kwd><kwd>palms [D010163]</kwd><kwd>soles [D005528 (Foot)]</kwd><kwd>nail bed [D009262 (Nails)]</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed B, Qadir MI, Ghafoor S. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028454 PMID: 32894659.</mixed-citation><mixed-citation xml:lang="en">1 Ahmed B, Qadir MI, Ghafoor S. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028454 PMID: 32894659.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023 Aug 5;402(10400):485-502. https://doi.org/10.1016/S0140-6736(23)00821-8 Epub 2023 Jul 24. Erratum in: Lancet. 2023 Aug 5;402(10400):450. PMID: 37499671.</mixed-citation><mixed-citation xml:lang="en">2 Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023 Aug 5;402(10400):485-502. https://doi.org/10.1016/S0140-6736(23)00821-8 Epub 2023 Jul 24. Erratum in: Lancet. 2023 Aug 5;402(10400):450. PMID: 37499671.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther. 2022 Dec;240:108301. https://doi.org/10.1016/j.pharmthera.2022.108301 Epub 2022 Oct 23. PMID: 36283453.</mixed-citation><mixed-citation xml:lang="en">3 Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther. 2022 Dec;240:108301. https://doi.org/10.1016/j.pharmthera.2022.108301 Epub 2022 Oct 23. PMID: 36283453.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC, Bray F. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022 May 1;158(5):495-503. https://doi.org/10.1001/jamadermatol.2022.0160 PMID: 35353115; PMCID: PMC8968696.</mixed-citation><mixed-citation xml:lang="en">4 Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC, Bray F. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022 May 1;158(5):495-503. https://doi.org/10.1001/jamadermatol.2022.0160 PMID: 35353115; PMCID: PMC8968696.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, Vázquez-Cruz ME, Garcia-Salinas OI, Álvarez-Cano A, Martínez-Said H, RoldánMarín R, Adams DJ, Possik PA, Robles-Espinoza CD. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2021 Jan;34(1):59-71. https://doi.org/10.1111/pcmr.12885 Epub 2020 Jun 17. PMID: 32330367; PMCID: PMC7818404.</mixed-citation><mixed-citation xml:lang="en">5 Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, Vázquez-Cruz ME, Garcia-Salinas OI, Álvarez-Cano A, Martínez-Said H, RoldánMarín R, Adams DJ, Possik PA, Robles-Espinoza CD. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2021 Jan;34(1):59-71. https://doi.org/10.1111/pcmr.12885 Epub 2020 Jun 17. PMID: 32330367; PMCID: PMC7818404.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kuchelmeister C., Schaumburg-Lever G., Garbe C. Acral cutaneous mela-noma in caucasians: clinical features, histopathology and prognosis in 112 patients. J. Dermatol. 2000;143:275–280.</mixed-citation><mixed-citation xml:lang="en">6 Kuchelmeister C., Schaumburg-Lever G., Garbe C. Acral cutaneous mela-noma in caucasians: clinical features, histopathology and prognosis in 112 patients. J. Dermatol. 2000;143:275–280.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Seiji M., Takematsu H., Hosokawa M., et al. Acral melanoma in Japan. J. Invest Dermatol. 1983;80:56-60.</mixed-citation><mixed-citation xml:lang="en">7 Seiji M., Takematsu H., Hosokawa M., et al. Acral melanoma in Japan. J. Invest Dermatol. 1983;80:56-60.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2013; 289 c.</mixed-citation><mixed-citation xml:lang="en">8 Chissov V.I., Starinskiy V.V., Petrova G.V. Zlokachestvennyye novoobrazovaniya v Rossii v 2011 godu (zabolevayemost′ i smert-nost′). M.: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii. 2013; 289 c. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Imyanitov E.N., Abysheva S.N., Iyevleva A.G., et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011;21:555–559.</mixed-citation><mixed-citation xml:lang="en">9 Imyanitov E.N., Abysheva S.N., Iyevleva A.G., et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011;21:555–559.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, Robles-Espinoza CD, Possik PA. More than just acral melanoma: the controversies of defining the disease. J Pathol Clin Res. 2021 Nov;7(6):531-541. https://doi.org/10.1002/cjp2.233 Epub 2021 Jul 2. PMID: 34213090; PMCID: PMC8503895.</mixed-citation><mixed-citation xml:lang="en">10 Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, Robles-Espinoza CD, Possik PA. More than just acral melanoma:the controversies of defining the disease. J Pathol Clin Res. 2021 Nov;7(6):531-541. https://doi.org/10.1002/cjp2.233 Epub 2021 Jul 2. PMID: 34213090; PMCID: PMC8503895.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jung S, Johnson DB. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. Oncologist. 2022 Aug 5;27(8):703-710. https://doi.org/10.1093/oncolo/oyac091 PMID: 35640549; PMCID: PMC9355814.</mixed-citation><mixed-citation xml:lang="en">11 Jung S, Johnson DB. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. Oncologist. 2022 Aug 5;27(8):703-710. https://doi.org/10.1093/oncolo/oyac091 PMID: 35640549; PMCID: PMC9355814.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Pan J, Wang M, Su J. Research hotspots and frontiers in acral melanoma: A bibliometric analysis from 1999 to 2023. Heliyon. 2023 Dec 19;10(1):e23720. https://doi.org/10.1016/j.heliyon.2023.e23720 PMID: 38226247; PMCID: PMC10788444.</mixed-citation><mixed-citation xml:lang="en">12 Wang Y, Pan J, Wang M, Su J. Research hotspots and frontiers in acral melanoma: A bibliometric analysis from 1999 to 2023. Heliyon. 2023 Dec 19;10(1):e23720. https://doi.org/10.1016/j.heliyon.2023.e23720 PMID: 38226247; PMCID: PMC10788444.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Tian H, Mao L, Si L. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies. Crit Rev Oncol Hematol. 2024 Jan;193:104221. https://doi.org/10.1016/j.critrevonc.2023.104221 Epub 2023 Nov 29. PMID: 38036156.</mixed-citation><mixed-citation xml:lang="en">13 Zhang J, Tian H, Mao L, Si L. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies. Crit Rev Oncol Hematol. 2024 Jan;193:104221. https://doi.org/10.1016/j.critrevonc.2023.104221 Epub 2023 Nov 29. PMID: 38036156.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Lan S, Wu D. Advanced Acral Melanoma Therapies: Current Status and Future Directions. Curr Treat Options Oncol. 2022 Oct;23(10):1405-1427. https://doi.org/10.1007/s11864-022-01007-6 Epub 2022 Sep 20. PMID: 36125617; PMCID: PMC9526689.</mixed-citation><mixed-citation xml:lang="en">14 Zhang Y, Lan S, Wu D. Advanced Acral Melanoma Therapies: Current Status and Future Directions. Curr Treat Options Oncol. 2022 Oct;23(10):1405-1427. https://doi.org/10.1007/s11864-022-01007-6 Epub 2022 Sep 20. PMID: 36125617; PMCID: PMC9526689.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Goydos JS, Shoen SL. Acral Lentiginous Melanoma. Cancer Treat Res. 2016;167:321-9. https://doi.org/10.1007/978-3-319-22539-5_14 PMID: 26601870.</mixed-citation><mixed-citation xml:lang="en">15 Goydos JS, Shoen SL. Acral Lentiginous Melanoma. Cancer Treat Res. 2016;167:321-9. https://doi.org/10.1007/978-3-319-22539-5_14 PMID: 26601870.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Perez MC, Messina JL, Karapetyan L, Neves RI, Sondak VK. Acral melanoma: clinical advances and hope for the future. Clin Adv Hematol Oncol. 2023 Aug;21(8):400-409. PMID: 37530614.</mixed-citation><mixed-citation xml:lang="en">16 Perez MC, Messina JL, Karapetyan L, Neves RI, Sondak VK. Acral melanoma: clinical advances and hope for the future. Clin Adv Hematol Oncol. 2023 Aug;21(8):400-409. PMID: 37530614.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Andre J, Sass U, Theunis A. Chapter 23: Diseases of the nails. In: McKee's Pathology of the Skin, Volume 2 ( 5th edn), E Calonje, T Brenn, A Lazar, et al. (Eds). Elsevier: Edinburgh, 2019; 1129–1155.</mixed-citation><mixed-citation xml:lang="en">17 Andre J, Sass U, Theunis A. Chapter 23: Diseases of the nails. In: McKee's Pathology of the Skin, Volume 2 ( 5th edn), E Calonje, T Brenn, A Lazar, et al. (Eds). Elsevier: Edinburgh, 2019; 1129–1155.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011 Jan;38(1):25-34. https://doi.org/10.1111/j.1346-8138.2010.01174.x PMID: 21175752.</mixed-citation><mixed-citation xml:lang="en">18 Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011 Jan;38(1):25-34. https://doi.org/10.1111/j.1346-8138.2010.01174.x PMID: 21175752.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, Mun JH. Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019 Sep;81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081 Epub 2019 Feb 5. PMID: 30731177.</mixed-citation><mixed-citation xml:lang="en">19 Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, Mun JH. Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019 Sep;81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081 Epub 2019 Feb 5. PMID: 30731177.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018 Jun 27;19(8):42. https://doi.org/10.1007/s11864-018-0560-y PMID: 29951919.</mixed-citation><mixed-citation xml:lang="en">20 Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018 Jun 27;19(8):42. https://doi.org/10.1007/s11864-018-0560-y PMID: 29951919.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
